{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:20:10Z","timestamp":1788884410366,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T00:00:00Z","timestamp":1512691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T00:00:00Z","timestamp":1512691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although depression with anxious distress appears to be a clinically relevant subtype of major depressive disorder (MDD), whether it involves specific pathophysiology remains unclear. Inflammation has been implicated, but not comprehensively studied. We examined within a large MDD sample whether anxious distress and related anxiety features are associated with differential basal inflammation and innate cytokine production capacity. Data are from 1078 MDD patients from the Netherlands Study of Depression and Anxiety. In addition to the DSM-5 anxious distress specifier, we studied various dimensional anxiety scales (e.g. Inventory of Depressive Symptomatology anxiety arousal subscale [IDS-AA], Beck Anxiety Inventory [BAI], Mood and Anxiety Symptoms Questionnaire Anxious Arousal scale [MASQ-AA]). The specifier was constructed using five self-report items from the IDS and BAI. Basal inflammatory markers included C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-\u03b1. Innate production capacity was assessed by 13 lipopolysaccharide (LPS)-stimulated inflammatory markers. Basal and LPS-stimulated inflammation index scores were created. Basal inflammation was not associated with anxious distress (prevalence\u2009=\u200954.3%) in MDD patients, except for a modest positive association for BAI score. However, anxious distress was associated with higher LPS-stimulated levels (interferon-\u03b3, IL-6, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1\u03b1, matrix metalloproteinase\u00a0(MMP)-2, TNF-\u03b1, LPS-stimulated index). Other anxiety indicators (anxious distress specifier score, BAI, MASQ-AA) were also associated with increased innate production capacity. Within a large MDD sample, the anxious distress specifier was associated with increased innate cytokine production capacity but not with basal inflammation. Results from dimensional anxiety indicators largely confirm these results. These findings provide new insight into the pathophysiology of anxious depression.<\/jats:p>","DOI":"10.1038\/s41398-017-0016-3","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T09:35:46Z","timestamp":1512552946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["The role of anxious distress in immune dysregulation in patients with major depressive disorder"],"prefix":"10.1038","volume":"7","author":[{"given":"Roxanne","family":"Gaspersz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Lamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle","family":"Wittenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aartjan T. F.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert M.","family":"van Hemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W. J. H.","family":"Penninx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/da.21939","volume":"29","author":"D Goldberg","year":"2012","unstructured":"Goldberg, D. & Fawcett, J. The importance of anxiety in both major depression and bipolar disorder. Depress. Anxiety 29, 471\u2013478 (2012).","journal-title":"Depress. Anxiety"},{"key":"16_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4088\/JCP.15m10221","volume":"78","author":"R Gaspersz","year":"2017","unstructured":"Gaspersz, R. et al. Longitudinal predictive validity of the DSM-5 anxious distress specifier for clinical outcomes in a large cohort of patients with major depressive disorder. J. Clin. Psychiatry 78, 207\u2013213 (2017).","journal-title":"J. Clin. Psychiatry"},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jad.2015.08.006","volume":"187","author":"JH Baek","year":"2015","unstructured":"Baek, J. H. et al. Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. J. Affect. Disord. 187, 183\u2013187 (2015).","journal-title":"J. Affect. Disord."},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/NMD.0b013e3182043b60","volume":"199","author":"HJ Seo","year":"2011","unstructured":"Seo, H. J. et al. Distinctive clinical characteristics and suicidal tendencies of patients with anxious depression. J. Nerv. Ment. Dis. 199, 42\u201348 (2011).","journal-title":"J. Nerv. Ment. Dis."},{"key":"16_CR5","first-page":"898","volume":"30","author":"J Fawcett","year":"2013","unstructured":"Fawcett, J. Suicide and anxiety in DSM-5. Depress. Anxiety 30, 898\u2013901 (2013).","journal-title":"Depress. Anxiety"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/2040622315627805","volume":"7","author":"RS McIntyre","year":"2016","unstructured":"McIntyre, R. S. et al The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Ther. Adv. Chronic Dis. 7, 153\u2013159 (2016).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jad.2013.03.012","volume":"150","author":"Z Wu","year":"2013","unstructured":"Wu, Z. et al. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. J. Affect. Disord. 150, 834\u2013839 (2013).","journal-title":"J. Affect. Disord."},{"key":"16_CR8","doi-asserted-by":"crossref","unstructured":"Ionescu D. F., Niciu M. J., Richards E. M. & Zarate C. A. J. Pharmacologic treatment of dimensional anxious depression: a review. Prim. Care Companion CNS Disord. 16, PCC.13r01621 (2014).","DOI":"10.4088\/PCC.13r01621"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","volume":"165","author":"M Fava","year":"2008","unstructured":"Fava, M. et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry 165, 342\u2013351 (2008).","journal-title":"Am. J. Psychiatry"},{"key":"16_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpsychires.2016.09.018","volume":"84","author":"R Gaspersz","year":"2017","unstructured":"Gaspersz, R. et al. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment. J. Psychiatr. Res. 84, 41\u201348 (2017).","journal-title":"J. Psychiatr. Res."},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/da.22095","volume":"30","author":"DF Ionescu","year":"2013","unstructured":"Ionescu, D. F., Niciu, M. J., Mathews, D. C., Richards, E. M. & Zarate, C. A. J. Neurobiology of anxious depression: a review. Depress. Anxiety 30, 374\u2013385 (2013).","journal-title":"Depress. Anxiety"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/0006-3223(94)00132-M","volume":"37","author":"WH Meller","year":"1995","unstructured":"Meller, W. H. et al. CRH challenge test in anxious depression. Biol. Psychiatry 37, 376\u2013382 (1995).","journal-title":"Biol. Psychiatry"},{"key":"16_CR13","first-page":"24","volume":"7","author":"OG Cameron","year":"2006","unstructured":"Cameron, O. G. Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergic functions. Essent. Psychopharmacol. 7, 24\u201334 (2006).","journal-title":"Essent. Psychopharmacol."},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/hup.1011","volume":"24","author":"BE Leonard","year":"2009","unstructured":"Leonard, B. E. & Myint, A. The psychoneuroimmunology of depression. Hum. Psychopharmacol. 24, 165\u2013175 (2009).","journal-title":"Hum. Psychopharmacol."},{"key":"16_CR15","doi-asserted-by":"crossref","unstructured":"Crane N. A. et al. Comorbid anxiety increases cognitive control activation in major depressive disorder. Depress. Anxiety 33, 967\u2013977 (2016). http:\/\/doi.org\/10.1002\/da.22541.''.","DOI":"10.1002\/da.22541"},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1017\/neu.2014.46","volume":"27","author":"DF Ionescu","year":"2015","unstructured":"Ionescu, D. F. et al. Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. Acta Neuropsychiatr. 27, 143\u2013152 (2015).","journal-title":"Acta Neuropsychiatr."},{"key":"16_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2016","unstructured":"Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22\u201334 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"16_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","volume":"65","author":"AH Miller","year":"2009","unstructured":"Miller, A. H., Maletic, V. & Raison, C. L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732\u2013741 (2009).","journal-title":"Biol. Psychiatry"},{"key":"16_CR19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.euroneuro.2017.04.001","volume":"27","author":"CM Pariante","year":"2017","unstructured":"Pariante, C. M. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur. Neuropsychopharmacol. 27, 554\u2013559 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"16_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","volume":"71","author":"MB Howren","year":"2009","unstructured":"Howren, M. B., Lamkin, D. M. & Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171\u2013186 (2009).","journal-title":"Psychosom. Med."},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446\u2013457 (2010).","journal-title":"Biol. Psychiatry"},{"key":"16_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jad.2011.08.003","volume":"139","author":"Y Liu","year":"2012","unstructured":"Liu, Y., Ho, R. C.-M. & Mak, A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord. 139, 230\u2013239 (2012).","journal-title":"J. Affect. Disord."},{"key":"16_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.92","volume":"6","author":"N Vogelzangs","year":"2016","unstructured":"Vogelzangs, N., de Jonge, P., Smit, J. H., Bahn, S. & Penninx, B. W. Cytokine production capacity in depression and anxiety. Transl. Psychiatry 6, e825 (2016).","journal-title":"Transl. Psychiatry"},{"key":"16_CR24","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","volume":"25","author":"R Strawbridge","year":"2015","unstructured":"Strawbridge, R. et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur. Neuropsychopharmacol. 25, 1532\u20131543 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jad.2012.10.036","volume":"148","author":"LA Carvalho","year":"2013","unstructured":"Carvalho, L. A. et al. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect. Disord. 148, 136\u2013140 (2013).","journal-title":"J. Affect. Disord."},{"key":"16_CR26","doi-asserted-by":"crossref","unstructured":"Cattaneo A. et al. Absolute measurements of macrophage migration inhibitory factor and interleukin-1-beta mRNA levels accurately predict treatment response in depressed patients. Int. J. Neuropsychopharmacol 19, pyw045 (2016).","DOI":"10.1093\/ijnp\/pyw045"},{"key":"16_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.27","volume":"3","author":"N Vogelzangs","year":"2013","unstructured":"Vogelzangs, N., Beekman, A. T. F. & de Jonge, P. Penninx BWJH. Anxiety disorders and inflammation in a large adult cohort. Transl. Psychiatry 3, e249 (2013).","journal-title":"Transl. Psychiatry"},{"key":"16_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.psychres.2015.05.036","volume":"229","author":"M Furtado","year":"2015","unstructured":"Furtado, M. & Katzman, M. A. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 229, 37\u201348 (2015).","journal-title":"Psychiatry Res."},{"key":"16_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.eurpsy.2011.02.001","volume":"26","author":"T Liukkonen","year":"2011","unstructured":"Liukkonen, T. et al. The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 birth cohort study. Eur. Psychiatry 26, 363\u2013369 (2011).","journal-title":"Eur. Psychiatry"},{"key":"16_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.mehy.2013.07.006","volume":"81","author":"A Camacho","year":"2013","unstructured":"Camacho, A. Is anxious-depression an inflammatory state?. Med. Hypotheses 81, 577\u2013581 (2013).","journal-title":"Med. Hypotheses"},{"key":"16_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/mp.2016.46","volume":"21","author":"ML Wong","year":"2016","unstructured":"Wong, M. L. et al. Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Mol. Psychiatry. 21, 797\u2013805 (2016).","journal-title":"Mol. Psychiatry."},{"key":"16_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2012.12.008","volume":"31","author":"M Iwata","year":"2013","unstructured":"Iwata, M., Ota, K. T. & Duman, R. S. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav. Immun. 31, 105\u2013114 (2013).","journal-title":"Brain Behav. Immun."},{"key":"16_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature10759","volume":"481","author":"T Strowig","year":"2012","unstructured":"Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278\u2013286 (2012).","journal-title":"Nature"},{"key":"16_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/da.22084","volume":"30","author":"AH Miller","year":"2013","unstructured":"Miller, A. H., Haroon, E., Raison, C. L. & Felger, J. C. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety 30, 297\u2013306 (2013).","journal-title":"Depress. Anxiety"},{"key":"16_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.genhosppsych.2016.07.003","volume":"42","author":"IH Shim","year":"2016","unstructured":"Shim, I. H., Woo, Y. S. & Bahk, W. M. Associations between immune activation and the current severity of the \u201cwith anxious distress\u201d specifier in patients with depressive disorders. Gen. Hosp. Psychiatry 42, 27\u201331 (2016).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"16_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4306\/pi.2016.13.3.321","volume":"13","author":"JH Baek","year":"2016","unstructured":"Baek, J. H. et al. Reduced venous blood basophil count and anxious depression in patients with major depressive disorder. Psychiatry Investig. 13, 321\u2013326 (2016).","journal-title":"Psychiatry Investig."},{"key":"16_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0022-1759(98)00108-2","volume":"218","author":"MW van der Linden","year":"1998","unstructured":"van der Linden, M. W., Huizinga, T. W., Stoeken, D. J., Sturk, A. & Westendorp, R. G. Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. J. Immunol. Methods 218, 63\u201371 (1998).","journal-title":"J. Immunol. Methods"},{"key":"16_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.exger.2007.01.011","volume":"42","author":"AHJ van den Biggelaar","year":"2007","unstructured":"van den Biggelaar, A. H. J. et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp. Gerontol. 42, 693\u2013701 (2007).","journal-title":"Exp. Gerontol."},{"key":"16_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.gene.6364162","volume":"6","author":"AJM de Craen","year":"2005","unstructured":"de Craen, A. J. M. et al. Heritability estimates of innate immunity: an extended twin study. Genes Immun. 6, 167\u2013170 (2005).","journal-title":"Genes Immun."},{"key":"16_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1017\/S1092852913000114","volume":"18","author":"DF Ionescu","year":"2013","unstructured":"Ionescu, D. F., Niciu, M. J., Henter, I. D. & Zarate, C. A. Defining anxious depression: a review of the literature. CNS Spectr. 18, 252\u2013260 (2013).","journal-title":"CNS Spectr."},{"key":"16_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mpr.256","volume":"17","author":"BW Penninx","year":"2008","unstructured":"Penninx, B. W. et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int. J. Methods. Psychiatr. Res. 17, 121\u201340 (2008).","journal-title":"Int. J. Methods. Psychiatr. Res."},{"key":"16_CR42","unstructured":"World Health Organization. Composite International Diagnostic Interview, Core Version 2.1: Interviewer\u2019s manual (World Health Organization, 1997)."},{"key":"16_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1017\/S0033291700035558","volume":"26","author":"AJ Rush","year":"1996","unstructured":"Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B. & Trivedi, M. H. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol. Med. 26, 477\u2013486 (1996).","journal-title":"Psychol. Med."},{"key":"16_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck, A. T., Epstein, N., Brown, G. & Steer, R. A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 56, 893\u2013897 (1988).","journal-title":"J. Consult. Clin. Psychol."},{"key":"16_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jad.2009.12.020","volume":"125","author":"KJ Wardenaar","year":"2010","unstructured":"Wardenaar, K. J. et al. The structure and dimensionality of the Inventory of Depressive Symptomatology Self Report (IDS-SR) in patients with depressive disorders and healthy controls. J. Affect. Disord. 125, 146\u2013154 (2010).","journal-title":"J. Affect. Disord."},{"key":"16_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0005-7967(79)90041-X","volume":"17","author":"IM Marks","year":"1979","unstructured":"Marks, I. M. & Mathews, A. M. Brief standard self-rating for phobic patients. Behav. Res. Ther. 17, 263\u2013237 (1979).","journal-title":"Behav. Res. Ther."},{"key":"16_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.psychres.2009.03.005","volume":"179","author":"KJ Wardenaar","year":"2010","unstructured":"Wardenaar, K. J. et al. Development and validation of a 30-item short adaptation of the Mood and Anxiety Symptoms Questionnaire (MASQ). Psychiatry Res. 179, 101\u2013106 (2010).","journal-title":"Psychiatry Res."},{"key":"16_CR48","unstructured":"Peterson R. A. & Reiss S. Anxiety Sensitivity Index (International Diagnostic Systems Publishing Corporation, 1992)."},{"key":"16_CR49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0005-7967(90)90135-6","volume":"28","author":"TJ Meijer","year":"1990","unstructured":"Meijer, T. J., Miller, M. L., Metzger, R. L. & Borkovec, T. Development and validation of the Penn State Worry Questionnaire. Behav. Res. Ther. 28, 487\u2013495 (1990).","journal-title":"Behav. Res. Ther."},{"key":"16_CR50","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig, C. L. et al. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports. Exerc. 35, 1381\u20131395 (2003).","journal-title":"Med. Sci. Sports. Exerc."},{"key":"16_CR51","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush, A. J. et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54, 573\u2013583 (2003).","journal-title":"Biol. Psychiatry"},{"key":"16_CR52","unstructured":"World Health Organization. World Health Organization Collaborating Centre for Drug Statistics Methodology (World Health Organization, 2007)."},{"key":"16_CR53","unstructured":"J. Cohen. Statistical Power Analysis for the Behavioral Sciences (Lawrence Erlbaum Associates, 1988)."},{"key":"16_CR54","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10592-005-9056-y","volume":"7","author":"SR Narum","year":"2006","unstructured":"Narum, S. R. Beyond Bonferroni: less conservative analyses for conservation genetics. Conserv. Genet. 7, 783\u2013787 (2006).","journal-title":"Conserv. Genet."},{"key":"16_CR55","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1214\/aos\/1013699998","volume":"29","author":"Y Benjamini","year":"2001","unstructured":"Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. Ann. Statist. 29, 1165\u20131188 (2001).","journal-title":"Ann. Statist."},{"key":"16_CR56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1385\/IR:30:3:261","volume":"30","author":"TW Du Clos","year":"2004","unstructured":"Du Clos, T. W. & Mold, C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res. 30, 261\u2013277 (2004).","journal-title":"Immunol. Res."},{"key":"16_CR57","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","volume":"150","author":"V Valkanova","year":"2013","unstructured":"Valkanova, V., Ebmeier, K. P. & Allan, C. L. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 150, 736\u201344 (2013).","journal-title":"J. Affect. Disord."},{"key":"16_CR58","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/ije\/dyp199","volume":"38","author":"OP Almeida","year":"2009","unstructured":"Almeida, O. P. et al. Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: the Health in Men Study. Int. J. Epidemiol. 38, 1049\u20131059 (2009).","journal-title":"Int. J. Epidemiol."},{"key":"16_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/npp.2016.169","volume":"42","author":"J Barnes","year":"2017","unstructured":"Barnes, J., Mondelli, V. & Pariante, C. M. Genetic contributions of inflammation to depression. Neuropsychopharmacology 42, 81\u201398 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"16_CR60","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.psyneuen.2013.01.002","volume":"38","author":"HE Duivis","year":"2013","unstructured":"Duivis, H. E., Vogelzangs, N., Kupper, N. & de Jonge, P. Penninx BWJH. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 38, 1573\u20131585 (2013).","journal-title":"Psychoneuroendocrinology"},{"key":"16_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biopsycho.2005.08.009","volume":"74","author":"BH Friedman","year":"2007","unstructured":"Friedman, B. H. An autonomic flexibility-neurovisceral integration model of anxiety and cardiac vagal tone. Biol. Psychol. 74, 185\u2013199 (2007).","journal-title":"Biol. Psychol."},{"key":"16_CR62","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.psyneuen.2008.08.007","volume":"33","author":"A Haensel","year":"2008","unstructured":"Haensel, A., Mills, P. J., Nelesen, R. A., Ziegler, M. G. & Dimsdale, J. E. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology. 33, 1305\u20131312 (2008).","journal-title":"Psychoneuroendocrinology."},{"key":"16_CR63","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1365-2362.2011.02485.x","volume":"41","author":"A Haarala","year":"2011","unstructured":"Haarala, A. et al. Heart rate variability is independently associated with C-reactive protein but not with Serum amyloid A. The Cardiovascular Risk in Young Finns Study. Eur. J. Clin. Invest. 41, 951\u2013957 (2011).","journal-title":"Eur. J. Clin. Invest."},{"key":"16_CR64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0140-6736(96)06413-6","volume":"349","author":"RG Westendorp","year":"1997","unstructured":"Westendorp, R. G. et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349, 170\u2013173 (1997).","journal-title":"Lancet"},{"key":"16_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-129","volume":"11","author":"Penninx BWJH","year":"2013","unstructured":"BWJH, Penninx., Milaneschi., Lamers, Y. & Vogelzangs, F. N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 11, 129 (2013).","journal-title":"BMC Med."},{"key":"16_CR66","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4088\/JCP.v66n0807","volume":"66","author":"JS Novick","year":"2005","unstructured":"Novick, J. S. et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J. Clin. Psychiatry 66, 1002\u20131011 (2005).","journal-title":"J. Clin. Psychiatry"},{"key":"16_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/10401230600614496","volume":"18","author":"AY Khan","year":"2006","unstructured":"Khan, A. Y. et al. Clinical and demographic factors associated with DSM-IV melancholic depression. Ann. Clin. Psychiatry 18, 91\u201398 (2006).","journal-title":"Ann. Clin. Psychiatry"},{"key":"16_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison, C. L. et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31\u201341 (2013).","journal-title":"JAMA Psychiatry"},{"key":"16_CR69","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","volume":"71","author":"O Kohler","year":"2014","unstructured":"Kohler, O. et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71, 1381\u20131391 (2014).","journal-title":"JAMA Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-017-0016-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-017-0016-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-017-0016-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T09:48:46Z","timestamp":1719654526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-017-0016-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":69,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1038\/s41398-017-0016-3","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]},"assertion":[{"value":"23 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.W.J.H.P. has received (non-related) research funding from Janssen Research & Development, LLC, and Boehringer Ingelheim. F.L. has received funding from the European Union Seventh Framework Programme (FP7\/2007-2013) under grant agreement no. PCIG12-GA-2012-334065. G.W. is a full-time employee of Janssen Research & Development, LLC, and holds stock in Johnson & Johnson. A.T.F.B. has served as a speaker for Lundbeck. The remaining authors declare that they have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1268"}}